Literature DB >> 21102353

Development of T-cell acute lymphoblastic leukemia in a patient in very long lasting complete remission of juvenile myelomonocytic leukemia.

Alexei A Maschan1, Lili A Khachatrian, Galina G Solopova, Elena Yu Ossipova, Luidmila V Baidun, Svetlana V Dmitrieva, Mikhail A Maschan, Igor B Resnik.   

Abstract

Juvenile myelomonocytic leukemia (JMML) occurs with an incidence of 1.2 per million children a year, and represents 18% to 30% of all myelodysplastic (MDS) and myeloproliferative (MPS) disorders in the age group below 15, being by far the most common MDS/MPS in children younger than 4 years. The only therapeutic approach which results in a definitive cure of patients with JMML is myeloablative chemo-therapy/radio-therapy, followed by allogeneic hematopoietic cell transplantation. Few cases of transformation of JMML in acute lymphoblastic leukemia have been reported. We describe a child with JMML diagnosed at the age of 4 months in whom complete remission was achieved with 13-cis retinoic acid and cytosine-arabinoside and was sustained for 7 years with no maintenance therapy. Ninety-eight months after the diagnosis of JMML was established, overt T-cell leukemia developed. Treatment with acute lymphoblastic leukemia (ALL)-directed chemotherapy induced complete restoration of normal hemopoiesis, but testicular involvement persisted. The patient died after transplantation with unrelated cord blood. This case suggests that JMML is a true stem cell disorder and that stem cell transplantation should be considered, even in patients with a very favorable clinical course.

Entities:  

Mesh:

Year:  2011        PMID: 21102353     DOI: 10.1097/MPH.0b013e3181f46e3e

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.

Authors:  Katherine R Calvo; Susan Price; Raul C Braylan; Joao Bosco Oliveira; Michael Lenardo; Thomas A Fleisher; V Koneti Rao
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

2.  RARS with fibrosis and del(20q) transformed into ALL.

Authors:  Sandra S Rohr; Luís Arthur Flores Pelloso; Aline dos Santos Borgo; João Garibaldi de Rezende; Maria Regina Regis Silva; Mihoko Yamamoto; Maria de Lourdes L F Chauffaille
Journal:  Med Oncol       Date:  2012-07-04       Impact factor: 3.064

3.  Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice.

Authors:  Stefan P Tarnawsky; Wen-Mei Yu; Cheng-Kui Qu; Rebecca J Chan; Mervin C Yoder
Journal:  Oncotarget       Date:  2018-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.